Gain-of-function p53R175H blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma

被引:3
|
作者
Haagsma, Jacob [1 ,2 ]
Kolendowski, Bart [1 ]
Buensuceso, Adrian [1 ,2 ]
Valdes, Yudith Ramos [1 ]
DiMattia, Gabriel E. [1 ,3 ,4 ]
Shepherd, Trevor G. [1 ,2 ,3 ,5 ,6 ]
机构
[1] London Reg Canc Program, Mary & John Knight Translat Ovarian Canc Res Unit, London, ON, Canada
[2] Western Univ, Schulich Sch Med & Dent, Dept Anat & Cell Biol, London, ON, Canada
[3] Western Univ, Schulich Sch Med & Dent, Dept Oncol, London, ON, Canada
[4] Western Univ, Schulich Sch Med & Dent, Dept Biochem, London, ON, Canada
[5] Western Univ, Schulich Sch Med & Dent, Dept Obstet & Gynaecol, London, ON, Canada
[6] London Reg Canc Program, 790 Commissioners Rd East,Room A4-836, London, ON N6A 4L6, Canada
基金
加拿大健康研究院;
关键词
P53; MUTANTS; WILD-TYPE; CANCER; P73; MUTATIONS; SURVIVAL; TP53; GENE; P63; DISRUPTION;
D O I
10.1038/s41598-023-38609-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Ovarian high-grade serous carcinoma (HGSC) is a highly lethal malignancy for which early detection is a challenge and treatment of late-stage disease is ineffective. HGSC initiation involves exfoliation of fallopian tube epithelial (FTE) cells which form multicellular clusters called spheroids that colonize and invade the ovary. HGSC contains universal mutation of the tumour suppressor gene TP53. However, not all TP53 mutations are the same, as specific p53 missense mutants contain gain-of-function (GOF) properties that drive tumour formation. Additionally, the role of GOF p53 in spheroid-mediated spread is poorly understood. In this study, we developed and characterized an in vitro model of HGSC based on mutation of TP53 in mouse oviductal epithelial cells (OVE). We discovered increased bulk spheroid survival and increased anchorage-independent growth in OVE cells expressing the missense mutant p53(R175H) compared to OVE parental and Trp53ko cells. Transcriptomic analysis on spheroids identified decreased apoptosis signaling due to p53(R175H). Further assessment of the apoptosis pathway demonstrated decreased expression of intrinsic and extrinsic apoptosis signaling molecules due to Trp53 deletion and p53(R175H), but Caspase-3 activation was only decreased in spheroids with p53(R175H). These results highlight this model as a useful tool for discovering early HGSC transformation mechanisms and uncover a potential anti-apoptosis GOF mechanism of p53(R175H).
引用
收藏
页数:14
相关论文
共 50 条
  • [31] p53-R172H mutation confers gain-of-function properties and promotes metastasis in squamous cell carcinoma
    Efe, Gizem
    Cunningham, Katherine
    de Bobadilla, Raul Navaridas Fernandez
    Dunbar, Karen J.
    Sugiura, Kensuke
    Nishiwaki, Noriyuki
    Carcamo, Saul
    Resnick-Silverman, Lois
    Hasson, Dan
    Klein-Szanto, Andres J.
    Taylor, Alison M.
    Manfredi, James J.
    Prives, Carol
    Rustgi, Anil K.
    CANCER RESEARCH, 2024, 84 (06)
  • [32] Immunohistochemical Expression of p53 Gene and Clinicopathological Assessment of Low-grade Serous Ovarian Cancer and High-grade Serous Ovarian Cancer: A Cohort Study
    Bazard, Geeta
    Vashist, Minakshi
    Singh, Sunita
    Rohilla, Gulshan
    Paliwal, Nidhi
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2024, 18 (12) : QC10 - QC14
  • [33] High-grade serous ovarian carcinoma detected with TP53 mutation panel and SiMSen-Seq
    Widjaja, Amanda Olsson
    Micallef, Peter
    Ulfenborg, Benjamin
    Lycke, Maria
    Gyllensten, Ulf
    Carlsson, Therese
    Osterlund, Tobias
    Stahlberg, Anders
    Linder, Anna
    Sundfeldt, Karin
    CANCER RESEARCH, 2024, 84 (06)
  • [34] Correlation of p53 Immunohistochemical Expression with TP53 Mutation in Extrauterine High-Grade Serous Carcinoma
    Karim, Lina Abdul
    Yang, Richard
    Ramalingam, Preetha
    Lawson, Barrett
    Malpica, Anais
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 639 - 640
  • [35] Characterization ofTP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma
    Chui, M. Herman
    Boroujeni, Amir Momeni
    Mandelker, Diana
    Ladanyi, Marc
    Soslow, Robert A.
    MODERN PATHOLOGY, 2021, 34 (02) : 490 - 501
  • [36] A novel peptide that restores p53 function may act synergistically with carboplatin in targeting high-grade serous ovarian cancers
    Lai, T.
    Neal, A.
    Grogan, T.
    Soragni, A.
    Memarzadeh, S.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 254 - 254
  • [37] Correlation of p53 Immunohistochemical Expression with TP53 Mutation in Extrauterine High-Grade Serous Carcinoma
    Karim, Lina Abdul
    Yang, Richard
    Ramalingam, Preetha
    Lawson, Barrett
    Malpica, Anais
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 639 - 640
  • [38] P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes.
    Mandilaras, Victoria
    Garg, Swati
    Burnier, Julia
    Karakasis, Katherine
    Wang, Lisa
    Mackay, Helen
    Dhani, Neesha C.
    Butler, Marcus O.
    Rodriguez-Freixinos, Victor
    Wilson, Michelle K.
    Martin-Lorente, Cristina
    Ethier, Josee-Lyne
    Bedard, Philippe L.
    Siu, Lillian L.
    Clarke, Blaise
    Shaw, Patricia Ann
    Stockley, Tracy
    Oza, Amit M.
    Lheureux, Stephanie
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] "The Blinded Guardian": clinical relevance of p53-null phenotype in high-grade serous ovarian cancers
    Parrella, V.
    Biatta, C. M.
    Paudice, M.
    Damiano, G.
    De Luca, G.
    Speciale, A.
    Cerruti, G.
    Mammoliti, S.
    Menichini, P.
    Vellone, V. G.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S111 - S112
  • [40] IDENTIFICATION OF P53 PRIONS AS AN INDEPENDENT PROGNOSTIC MARKER FOR SURVIVAL IN HIGH-GRADE SEROUS OVARIAN CANCER
    Heinzl, Nicole
    Maritschnegg, Elisabeth
    Koziel, Katarzyna
    Wilson, Stuart
    Heinze, Georg
    Wallisch, Christine
    Horvat, Reinhard
    Sehouli, Jalid
    Braicu, Ioana
    Vergote, Ignace
    van Nieuwenhuysen, Els
    Mahner, Sven
    Obermayr, Eva
    Schuster, Eva
    Holzer, Barbara
    Concin, Nicole
    Zeillinger, Robert
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 76 - 76